Bendamustine
Showing 1 - 25 of 372
Waldenström's Macroglobulinemia Trial (zanubrutinib,bendamustine,rituximab)
Not yet recruiting
- Waldenström's Macroglobulinemia
- (no location specified)
Aug 4, 2023
Amyloidosis, Light Chain (AL) Amyloidosis Trial (Bendamustine Hydrochloride, Isatuximab)
Withdrawn
- Amyloidosis
- Light Chain (AL) Amyloidosis
- Bendamustine Hydrochloride
- Isatuximab
- (no location specified)
Dec 29, 2022
Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)
Not yet recruiting
- Mantle-cell Lymphoma
- Polatuzumab, bendamustin und rituximab
- (no location specified)
May 11, 2023
Follicular Lymphoma Trial (Bendamustine, Rituximab, Tazemetostat)
Not yet recruiting
- Follicular Lymphoma
- Bendamustine
- +2 more
- (no location specified)
Dec 15, 2022
Multiple Myeloma Trial in Saint Louis (Isatuximab, Bendamustine, Prednisone)
Recruiting
- Multiple Myeloma
- Isatuximab
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Sep 21, 2022
Hodgkin Lymphoma Trial in Saint Petersburg (Prolgolimab, Combination with prolgolimab and bendamustine)
Recruiting
- Hodgkin Lymphoma
- Prolgolimab
- Combination with prolgolimab and bendamustine
-
Saint Petersburg, Russian Federation
- +1 more
Mar 3, 2023
Lymphoma, Mantle-Cell Trial in Shanghai (Zanubrutinib, Rituximab, Bendamustin)
Not yet recruiting
- Lymphoma, Mantle-Cell
- Zanubrutinib
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Nov 14, 2023
Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin Trial in Madison (Bendamustine, Rituximab, Lenalidomide)
Completed
- Lymphoid Leukemia
- +2 more
- Bendamustine
- +2 more
-
Madison, WisconsinUniversity of Wisconsin
Jan 30, 2023
Waldenstrom Macroglobulinemia Trial in Tianjin (Zanubrutinib, Bendamustine and Rituximab)
Recruiting
- Waldenstrom Macroglobulinemia
- Zanubrutinib, Bendamustine and Rituximab
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Jun 13, 2023
Lymphoma Trial in New York (rituximab, bendamustine, melphalan)
Active, not recruiting
- Lymphoma
- rituximab
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 10, 2023
CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive Trial in Atlanta, Johns Creek (Bendamustine, Obinutuzumab, Venetoclax)
Active, not recruiting
- CCND1 Positive
- +2 more
- Bendamustine
- +2 more
-
Atlanta, Georgia
- +2 more
Nov 2, 2022
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Madison (Bendamustine, Obinutuzumab)
Recruiting
- Mantle Cell Lymphoma
- +2 more
- Bendamustine
- Obinutuzumab
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Sep 13, 2022
Chronic Lymphocytic Leucemia Trial in Cologne (Bendamustine, GA101, ABT-199)
Active, not recruiting
- Chronic Lymphocytic Leucemia
- Bendamustine
- +2 more
-
Cologne, GermanyGerman CLL Study Group
Sep 14, 2022
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, MDS Trial in Tucson (Bendamustine, Cyclophosphamide)
Recruiting
- Acute Lymphoblastic Leukemia
- +12 more
- Bendamustine
- Cyclophosphamide
-
Tucson, ArizonaThe University of Arizona Cancer Center
Dec 13, 2022
Waldenstrom Macroglobulinemia Trial in Canada (Acalabrutinib, Bendamustine, Rituximab)
Recruiting
- Waldenstrom Macroglobulinemia
- Acalabrutinib
- +2 more
-
Calgary, Alberta, Canada
- +8 more
Nov 9, 2022
Hodgkin Lymphoma Trial in Moscow (Nivolumab)
Recruiting
- Hodgkin Lymphoma
-
Moscow, Russian FederationNational Research Center for Hematology
Dec 13, 2022
Mantle Cell Lymphoma Trial in United States (Venetoclax, Bendamustine, Rituximab)
Active, not recruiting
- Mantle Cell Lymphoma
- Venetoclax
- +2 more
-
Urbana, Illinois
- +9 more
Nov 10, 2022
Lymphoma Trial in Cairo (BEAM Protocol, CEM protocol)
Recruiting
- Lymphoma
- BEAM Protocol
- CEM protocol
-
Cairo, EgyptInternational Medical Center (IMC) Hospital, Cairo, Egypt.
Apr 1, 2023
Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)
Completed
- Non-Hodgkin's Lymphoma
- Bendamustine
- +6 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022
Diffuse, Large B-Cell, Lymphoma Trial in China (Polatuzumab Vedotin, Bendamustine, Rituximab)
Completed
- Diffuse, Large B-Cell, Lymphoma
- Polatuzumab Vedotin
- +3 more
-
Beijing, China
- +9 more
Jul 7, 2022
Chronic Lymphocytic Leucemia Trial in Cologne (Bendamustine, GA101, CAL-101)
Active, not recruiting
- Chronic Lymphocytic Leucemia
- Bendamustine
- +2 more
-
Cologne, GermanyGerman CLL Study Group
Apr 29, 2022
Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia Trial in Los Angeles (radiation, procedure, biological, drug)
Active, not recruiting
- Multiple Myeloma
- +4 more
- Total Body Irradiation
- +5 more
-
Los Angeles, CaliforniaCedars Sinai Medical Center
Dec 21, 2022
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer Trial in Toronto (Pembrolizumab, Bendamustine Hydrochloride)
Recruiting
- Classical Hodgkin Lymphoma
- +2 more
- Pembrolizumab
- Bendamustine Hydrochloride
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Dec 31, 2021